Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

The Life Sciences Report | |

To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and

How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations

The Life Sciences Report | |

After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to

The Best Performing Biotech Stocks Over the Last Quarter

Joe Goldman | |

Biotech stocks are a volatile bunch, and there is no shortage of big winners over the previous three months. Certainly not for the faint of heart, the direction of a biotech stock is typically

Intercept Pharmaceuticals (ICPT) Sees Pullback from Record Gains

Joel Anderson | |

Intercept Pharmaceuticals (ICPT) continued its wild, roller-coaster ride on Tuesday, with a second-straight day of major losses. Intercept made news last week after its treatment for fatty liver

DJIA, S&P, NASDAQ Rally on Better-than-Expected Retail Sales Data

Michael Teague | |

Stocks ended significantly higher by Tuesday’s closing bell, with indices rallying to gains big enough to recuperate most of the losses incurred during the previous day’s sell-off. The

Lowered Earnings Expectations send DJIA, S&P 500, and NASDAQ Into the Tank

Michael Teague | |

The shockingly dismal jobs report issued by the Department of Labor last week carried over into Monday’s trading session, exacerbating widespread expectations that the first earnings season

DJIA Retreats as Dismal Jobs Report is Celebrated on S&P 500, NASDAQ

Michael Teague | |

Stocks on Wall Street ended mostly higher on Friday to conclude the first full week of trading in 2014, with the Dow Jones Industrial average beating a slight retreat into negative territory. The

Intercept Pharmaceuticals (ICPT) Continues to Soar

Joel Anderson | |

Shares in biopharmaceutical company Intercept Pharmaceuticals (ICPT) spiked over 70 percent Friday before pulling pack to gains of around 60 percent, one day after shares soared more than 280

DJIA, NASDAQ Edge Lower as S&P Gains on Financials and Services

Michael Teague | |

Stocks were mostly lower at the conclusion of Thursday’s trading session, as Wall Street braces itself for what could be more good economic data in the form of Friday’s December jobs

Intercept Shares Skyrocket on NASH Trial Data, Galectin Shares Jump Too

Andrew Klips | |

Even those that have been around the market for decades don’t often see the type of move that shares of Intercept Pharmaceuticals, Inc. (ICPT) are making on Thursday. Shares have ballooned

Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure